Back

Infection-specific long-chain fatty acid metabolism as a broad anti-enterovirus target

Florentin, M.; Loube, J.; Viktorova, E. G.; Gabaglio, S.; Tanner, E.; Scull, M. A.; Belov, G. A.

2026-06-11 microbiology
10.64898/2026.06.10.731372 bioRxiv
Show abstract

Enteroviruses are arguably the most numerous group of viruses infecting humans. While most enterovirus infections are benign and self-resolving, their sheer number inevitably increases the chances of multiple complications. The diversity of enteroviruses means that the development of vaccines is only economically feasible against a select few, and no direct-acting or host-targeted anti-virals are approved to treat enteroviral infections, largely due to the rapid development of resistance against all experimental drugs. Here, we explored a universal property of enterovirus infection - a massive upregulation of phospholipid synthesis as a target for anti-viral interventions. The increased phospholipid synthesis consumes endogenously- and exogenously-derived long-chain fatty acids (LCFA). We demonstrate that polyunsaturated LCFAs can have a broad anti-enteroviral effect, affecting multiple steps of the virus life cycle. The anti-viral activity of LCFAs did not strictly depend on the degree of unsaturation or their capacity to induce lipid peroxidation but significantly correlated with their conformation. This suggests that their incorporation into the phospholipid molecules makes the replication organelle membranes incapable of properly accommodating viral replication machinery. Accordingly, the inhibition of neutral lipid synthesis promoted LCFAs retargeting to the membranes in infected cells and increased their anti-viral potency. We show that this approach is effective against diverse enteroviruses in different cell types, including differentiated primary cells, and that attempts to establish viruses resistant to such treatment were unsuccessful.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Journal of Virology
499 papers in training set
Top 0.8%
9.7%
2
mBio
833 papers in training set
Top 3%
6.7%
3
Nature Communications
5641 papers in training set
Top 27%
5.4%
4
Cell Chemical Biology
94 papers in training set
Top 0.2%
4.8%
5
Cell Reports
1498 papers in training set
Top 8%
4.8%
6
EMBO Reports
263 papers in training set
Top 0.9%
4.3%
7
Journal of Lipid Research
39 papers in training set
Top 0.1%
4.3%
8
ACS Infectious Diseases
82 papers in training set
Top 0.5%
3.2%
9
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 17%
3.2%
10
Cellular and Molecular Life Sciences
96 papers in training set
Top 0.3%
2.8%
11
iScience
1154 papers in training set
Top 11%
2.4%
50% of probability mass above
12
PLOS Pathogens
820 papers in training set
Top 6%
2.1%
13
Communications Biology
993 papers in training set
Top 11%
2.1%
14
Scientific Reports
3612 papers in training set
Top 48%
2.1%
15
The FEBS Journal
93 papers in training set
Top 0.6%
1.9%
16
EMBO Molecular Medicine
95 papers in training set
Top 0.8%
1.9%
17
Cell Reports Medicine
153 papers in training set
Top 2%
1.9%
18
PLOS Biology
486 papers in training set
Top 4%
1.9%
19
eLife
5828 papers in training set
Top 49%
1.7%
20
Science Advances
1243 papers in training set
Top 20%
1.7%
21
RSC Chemical Biology
39 papers in training set
Top 0.4%
1.4%
22
NAR Molecular Medicine
22 papers in training set
Top 0.2%
1.3%
23
Journal of Biological Chemistry
690 papers in training set
Top 7%
1.1%
24
Advanced Science
286 papers in training set
Top 7%
1.1%
25
Antiviral Research
50 papers in training set
Top 0.5%
1.1%
26
Journal of Hepatology
21 papers in training set
Top 0.3%
1.1%
27
mSphere
302 papers in training set
Top 6%
1.0%
28
eBioMedicine
183 papers in training set
Top 5%
1.0%
29
Angewandte Chemie International Edition
93 papers in training set
Top 2%
0.9%
30
ACS Chemical Biology
167 papers in training set
Top 3%
0.8%